Anticancer Drug Market by Drug Type and Therapy Type - Global Industry Analysis & Forecast to 2027
Published On : September 2019 Pages : 174 Category: Pharma & Healthcare Report Code : HC095504
Anticancer Drug Market by Drug Type (Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs, Others) Therapy Type (Targeted Therapy, Chemotherapy, Immunotherapy) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The anticancer drug market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Anticancer drug also known as antineoplastic drug, any medication that is compelling in the treatment of malignant, or cancerous, disease. There are a few noteworthy classes of anticancer medications; these incorporate alkylating operators, antimetabolites, natural products, and hormones. Also, there are various medications that don't fall inside those classes yet that exhibit anticancer movement and in this manner are utilized in the treatment of malignant disease.
Drivers and Restraints
Increasing healthcare expenditure drives the growth of anticancer drug market. Increasing prevalence of cancer propels the growth of anticancer drug market. Rapid development in drug infrastructure fuels the growth of anticancer drug market. The expanding accomplishment of medications shown by the expanding survival rates is the other factor expected to drive the development of the anticancer drugs market. Government initiatives contribute to the growth of anticancer drug market. Increasing awareness about anticancer drugs as well as increasing health care investments provides beneficial opportunities for the anticancer drug market.
Regional Insights
Among the geographies, North America is expected to dominate the anticancer drug market. Development in healthcare infrastructure and huge investments in healthcare in the region contribute to the growth of anticancer drug market.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- AbbVie Inc.
- Celgene
- Eli Lilly & Co
- Bayer, Pfizer Inc.
- Johnson & Johnson
- Novartis AG
- Roche Holding AG
- Bristol-Myers Squibb
- Astra Zeneca
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Anticancer Drug Market, By Drug Type, Estimates and Forecast, 2017-2027 ($Million)
o Cytotoxic Drugs
o Targeted Drugs
o Hormonal Drugs
o Others
· Anticancer Drug Market, By Therapy Type, Estimates and Forecast, 2017-2027 ($Million)
o Targeted Therapy
o Chemotherapy
o Immunotherapy
· Anticancer Drug Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o AbbVie Inc.
o Celgene
o Eli Lilly & Co
o Bayer, Pfizer Inc.
o Johnson & Johnson
o Novartis AG
o Roche Holding AG
o Bristol-Myers Squibb
o Astra Zeneca
· Anticancer Drug Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Anticancer Drug Market, By Country
o U.S. Anticancer Drug Market
o Canada Anticancer Drug Market
o Mexico Anticancer Drug Market
o Europe
§ Europe Anticancer Drug Market, By Country
· Germany Anticancer Drug Market
o UK Anticancer Drug Market
o France Anticancer Drug Market
o Russia Anticancer Drug Market
o Italy Anticancer Drug Market
o Rest of Europe Anticancer Drug Market
o Asia-Pacific
§ Asia-Pacific Anticancer Drug Market, By Country
o China Anticancer Drug Market
o Japan Anticancer Drug Market
o South Korea Anticancer Drug Market
o India Anticancer Drug Market
o Southeast Asia Anticancer Drug Market
o Rest of Asia-Pacific Anticancer Drug Market
o South America
§ South America Anticancer Drug Market
o Brazil Anticancer Drug Market
o Argentina Anticancer Drug Market
o Columbia Anticancer Drug Market
o Rest of South America Anticancer Drug Market
o Middle East and Africa
§ Middle East and Africa Anticancer Drug Market
o Saudi Arabia Anticancer Drug Market
o UAE Anticancer Drug Market
o Egypt Anticancer Drug Market
o Nigeria Anticancer Drug Market
o South Africa Anticancer Drug Market
o Rest of MEA Anticancer Drug Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Anticancer Drug Market, By Drug Type
5.1. Introduction
5.2. Global Anticancer Drug Revenue and Market Share by Drug Type (2017-2027)
5.2.1. Global Anticancer Drug Revenue and Revenue Share by Drug Type (2017-2027)
5.3. Cytotoxic Drugs
5.3.1. Global Cytotoxic Drugs Revenue and Growth Rate (2017-2027)
5.4. Targeted Drugs
5.4.1. Global Targeted Drugs Revenue and Growth Rate (2017-2027)
5.5. Hormonal Drugs
5.5.1. Global Hormonal Drugs Revenue and Growth Rate (2017-2027)
5.6. Others
5.6.1. Global Others Revenue and Growth Rate (2017-2027)
6. Anticancer Drug Market, By Therapy Type
6.1. Introduction
6.2. Global Anticancer Drug Revenue and Market Share by Therapy Type (2017-2027)
6.2.1. Global Anticancer Drug Revenue and Revenue Share by Therapy Type (2017-2027)
6.3. Targeted Therapy
6.3.1. Global Targeted Therapy Revenue and Growth Rate (2017-2027)
6.4. Chemotherapy
6.4.1. Global Chemotherapy Revenue and Growth Rate (2017-2027)
6.5. Immunotherapy
6.5.1. Global Immunotherapy Revenue and Growth Rate (2017-2027)
7. Anticancer Drug Market, By Region
7.1. Introduction
7.2. Global Anticancer Drug Revenue and Market Share by Regions
7.2.1. Global Anticancer Drug Revenue by Regions (2017-2027)
7.3. North America Anticancer Drug by Countries
7.3.1. North America Anticancer Drug Revenue and Growth Rate (2017-2027)
7.3.2. North America Anticancer Drug Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Anticancer Drug by Countries
7.4.1. Europe Anticancer Drug Revenue and Growth Rate (2017-2027)
7.4.2. Europe Anticancer Drug Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Anticancer Drug by Countries
7.5.1. Asia-Pacific Anticancer Drug Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Anticancer Drug Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Anticancer Drug by Countries
7.6.1. South America Anticancer Drug Revenue and Growth Rate (2017-2027)
7.6.2. South America Anticancer Drug Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Anticancer Drug by Countries
7.7.1. Middle East and Africa Anticancer Drug Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Anticancer Drug Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. AbbVie Inc.
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Celgene
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Eli Lilly & Co
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Bayer, Pfizer Inc.
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Johnson & Johnson
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Novartis AG
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Roche Holding AG
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Bristol-Myers Squibb
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. Astra Zeneca
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
9. Anticancer Drug Market Forecast (2017-2027)
9.1. Global Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. Anticancer Drug Market Forecast by Regions (2017-2027)
9.2.1. North America Anticancer Drug Market Forecast (2017-2027)
9.2.1.1. United States Anticancer Drug Market Forecast (2017-2027)
9.2.1.2. Canada Anticancer Drug Market Forecast (2017-2027)
9.2.1.3. Mexico Anticancer Drug Market Forecast (2017-2027)
9.2.2. Europe Anticancer Drug Market Forecast (2017-2027)
9.2.2.1. Germany Anticancer Drug Market Forecast (2017-2027)
9.2.2.2. France Anticancer Drug Market Forecast (2017-2027)
9.2.2.3. UK Anticancer Drug Market Forecast (2017-2027)
9.2.2.4. Russia Anticancer Drug Market Forecast (2017-2027)
9.2.2.5. Italy Anticancer Drug Market Forecast (2017-2027)
9.2.2.6. Rest of Europe Anticancer Drug Market Forecast (2017-2027)
9.2.3. Asia-Pacific Anticancer Drug Market Forecast (2017-2027)
9.2.3.1. China Anticancer Drug Market Forecast (2017-2027)
9.2.3.2. Japan Anticancer Drug Market Forecast (2017-2027)
9.2.3.3. Korea Anticancer Drug Market Forecast (2017-2027)
9.2.3.4. India Anticancer Drug Market Forecast (2017-2027)
9.2.3.5. Southeast Asia Anticancer Drug Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific Anticancer Drug Market Forecast (2017-2027)
9.2.4. South America Anticancer Drug Market Forecast (2017-2027)
9.2.4.1. Brazil Anticancer Drug Market Forecast (2017-2027)
9.2.4.2. Argentina Anticancer Drug Market Forecast (2017-2027)
9.2.4.3. Columbia Anticancer Drug Market Forecast (2017-2027)
9.2.4.4. Rest of South America Anticancer Drug Market Forecast (2017-2027)
9.2.5. Middle East and Africa Anticancer Drug Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia Anticancer Drug Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates Anticancer Drug Market Forecast (2017-2027)
9.2.5.3. Egypt Anticancer Drug Market Forecast (2017-2027)
9.2.5.4. Nigeria Anticancer Drug Market Forecast (2017-2027)
9.2.5.5. South Africa Anticancer Drug Market Forecast (2017-2027)
9.2.5.6. Turkey Anticancer Drug Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa Anticancer Drug Market Forecast (2017-2027)
9.3. Anticancer Drug Market Forecast by Drug Type (2017-2027)
9.3.1. Anticancer Drug Forecast by Drug Type (2017-2027)
9.3.2. Anticancer Drug Market Share Forecast by Drug Type (2017-2027)
9.4. Anticancer Drug Market Forecast by Therapy Type (2017-2027)
9.4.1. Anticancer Drug Forecast by Therapy Type (2017-2027)
9.4.2. Anticancer Drug Market Share Forecast by Therapy Type (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Anticancer Drug Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Anticancer Drug Revenue and Revenue Share by Drug Type (2017-2018)
Figure Global Cytotoxic Drugs Revenue and Growth Rate (2017-2018)
Figure Global Targeted Drugs Revenue and Growth Rate (2017-2018)
Figure Global Hormonal Drugs Revenue and Growth Rate (2017-2018)
Figure Global Others Revenue and Growth Rate (2017-2018)
Table Global Anticancer Drug Revenue and Revenue Share by Therapy Type (2017-2018)
Figure Global Targeted Therapy Revenue and Growth Rate (2017-2018)
Figure Global Chemotherapy Revenue and Growth Rate (2017-2018)
Figure Global Immunotherapy Revenue and Growth Rate (2017-2018)
Table Global Anticancer Drug Revenue by Regions (2017-2018)
Figure North America Anticancer Drug Growth Rate (2017-2018)
Figure North America Anticancer Drug Revenue and Growth Rate (2017-2018)
Figure North America Anticancer Drug by Countries (2017-2018)
Figure North America Anticancer Drug Revenue (Million USD) by Countries (2017-2018)
Figure United States Anticancer Drug Growth Rate (2017-2018)
Figure United States Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Anticancer Drug Growth Rate (2017-2018)
Figure Canada Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Anticancer Drug Growth Rate (2017-2018)
Figure Mexico Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Anticancer Drug Growth Rate (2017-2018)
Figure Europe Anticancer Drug Revenue and Growth Rate (2017-2018)
Figure Europe Anticancer Drug by Countries (2017-2018)
Figure Europe Anticancer Drug Revenue (Million USD) by Countries (2017-2018)
Figure Germany Anticancer Drug Growth Rate (2017-2018)
Figure Germany Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Anticancer Drug Growth Rate (2017-2018)
Figure France Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Anticancer Drug Growth Rate (2017-2018)
Figure UK Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Anticancer Drug Growth Rate (2017-2018)
Figure Russia Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Anticancer Drug Growth Rate (2017-2018)
Figure Italy Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Anticancer Drug Growth Rate (2017-2018)
Figure Rest of Europe Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Anticancer Drug Growth Rate (2017-2018)
Figure Asia-Pacific Anticancer Drug Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Anticancer Drug by Countries (2017-2018)
Figure Asia-Pacific Anticancer Drug Revenue (Million USD) by Countries (2017-2018)
Figure China Anticancer Drug Growth Rate (2017-2018)
Figure China Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Anticancer Drug Growth Rate (2017-2018)
Figure Japan Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Anticancer Drug Growth Rate (2017-2018)
Figure Korea Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Anticancer Drug Growth Rate (2017-2018)
Figure India Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Anticancer Drug Growth Rate (2017-2018)
Figure Southeast Asia Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Anticancer Drug Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Anticancer Drug Growth Rate (2017-2018)
Figure South America Anticancer Drug Revenue and Growth Rate (2017-2018)
Figure South America Anticancer Drug by Countries (2017-2018)
Figure South America Anticancer Drug Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Anticancer Drug Growth Rate (2017-2018)
Figure Brazil Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Anticancer Drug Growth Rate (2017-2018)
Figure Argentina Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Anticancer Drug Growth Rate (2017-2018)
Figure Columbia Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Anticancer Drug Growth Rate (2017-2018)
Figure Rest of South America Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Anticancer Drug Growth Rate (2017-2018)
Figure Middle East and Africa Anticancer Drug Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Anticancer Drug by Countries (2017-2018)
Figure Middle East and Africa Anticancer Drug Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Anticancer Drug Growth Rate (2017-2018)
Figure Saudi Arabia Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Anticancer Drug Growth Rate (2017-2018)
Figure United Arab Emirates Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Anticancer Drug Growth Rate (2017-2018)
Figure Egypt Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Anticancer Drug Growth Rate (2017-2018)
Figure Nigeria Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Anticancer Drug Growth Rate (2017-2018)
Figure South Africa Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Anticancer Drug Growth Rate (2017-2018)
Figure Turkey Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Anticancer Drug Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Anticancer Drug Revenue (Millions USD) and Growth Rate (2017-2018)
Table AbbVie Inc. Anticancer Drug Financial Overview
Table Celgene Anticancer Drug Financial Overview
Table Eli Lilly & Co Anticancer Drug Financial Overview
Table Bayer, Pfizer Inc. Anticancer Drug Financial Overview
Table Johnson & Johnson Anticancer Drug Financial Overview
Table Novartis AG Anticancer Drug Financial Overview
Table Roche Holding AG Anticancer Drug Financial Overview
Table Bristol-Myers Squibb Anticancer Drug Financial Overview
Table Astra Zeneca Anticancer Drug Financial Overview
Figure Global Anticancer Drug Revenue (Millions USD) and Growth Rate (2018-2025)
Table Anticancer Drug Market Forecast by Regions (2018-2025)
Figure North America Anticancer Drug Market Forecast (2018-2025)
Figure United States Anticancer Drug Market Forecast (2018-2025)
Figure Canada Anticancer Drug Market Forecast (2018-2025)
Figure Mexico Anticancer Drug Market Forecast (2018-2025)
Figure Europe Anticancer Drug Market Forecast (2018-2025)
Figure Germany Anticancer Drug Market Forecast (2018-2025)
Figure France Anticancer Drug Market Forecast (2018-2025)
Figure UK Anticancer Drug Market Forecast (2018-2025)
Figure Russia Anticancer Drug Market Forecast (2018-2025)
Figure Italy Anticancer Drug Market Forecast (2018-2025)
Figure Rest of Europe Anticancer Drug Market Forecast (2018-2025)
Figure Asia-Pacific Anticancer Drug Market Forecast (2018-2025)
Figure China Anticancer Drug Market Forecast (2018-2025)
Figure Japan Anticancer Drug Market Forecast (2018-2025)
Figure Korea Anticancer Drug Market Forecast (2018-2025)
Figure India Anticancer Drug Market Forecast (2018-2025)
Figure Southeast Asia Anticancer Drug Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Anticancer Drug Market Forecast (2018-2025)
Figure South America Anticancer Drug Market Forecast (2018-2025)
Figure Brazil Anticancer Drug Market Forecast (2018-2025)
Figure Argentina Anticancer Drug Market Forecast (2018-2025)
Figure Columbia Anticancer Drug Market Forecast (2018-2025)
Figure Rest of South America Anticancer Drug Market Forecast (2018-2025)
Figure Middle East and Africa Anticancer Drug Market Forecast (2018-2025)
Figure Saudi Arabia Anticancer Drug Market Forecast (2018-2025)
Figure United Arab Emirates Anticancer Drug Market Forecast (2018-2025)
Figure Egypt Anticancer Drug Market Forecast (2018-2025)
Figure Nigeria Anticancer Drug Market Forecast (2018-2025)
Figure South Africa Anticancer Drug Market Forecast (2018-2025)
Figure Turkey Anticancer Drug Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Anticancer Drug Market Forecast (2018-2025)
Figure Global Anticancer Drug Forecast by Drug Type (2018-2025)
Figure Global Anticancer Drug Market Share Forecast by Drug Type (2018-2025)
Figure Global Anticancer Drug Forecast by Drug Type (2018-2025)
Figure Global Anticancer Drug Forecast by Therapy Type (2018-2025)
Figure Global Anticancer Drug Market Share Forecast by Therapy Type (2018-2025)
Figure Global Anticancer Drug Forecast by Therapy Type (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|